STE
Steris
$200.40
▼ 1.1%Updated Today 7:15 PM ET
▼ Down 14.2% over the last 12 months
Market Cap
$19.75B
P/E
25.3x
Forward P/E (est.)
19.77x
ROE
11.1%
Revenue Growth
8.7%
EPS Growth
27.9%
Profit Margin
13.2%
FCF Yield
5.4%
Debt / Equity
0.27x
ROIC
10.0%
Interest Coverage
7.63x
Current Ratio
2.09x
Dividend Yield
1.2%
Implied Growth (rev. DCF)
3.9%
Rating Score
59/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what STE's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. STE trades near $200.40, below its 50-day average ($215.03) and 200-day average ($239.07). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 22 it is oversold — selling has been heavy and a bounce is possible.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently negative — short-term momentum is fading.
Volatility — ATR. Average True Range is the typical daily move. STE's is $4.72 (~2.4% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month STE found buyers near $198.01 (support) and sellers near $219.98 (resistance); its 52-week range is $195.14–$269.44. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.4× the 20-day average — heavier than usual, which adds conviction to the move. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Steris (STE) is a large-cap company in the Health Care Equipment industry, part of the Health Care sector of the S&P 500, with a market value around $19.75B.
In its latest reported year it generated about $5.94B in revenue and $782.30M in net profit.
Our model rates STE Favorable (59/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
8.9%
Revenue moved from $4.22B in 2022 to $5.94B in 2026, a 8.9% compound annual growth rate. The most recent year grew a steady 8.7% year over year. Slower, mature growth is common for established businesses.
Gross Margin
44.2%
Operating Margin
18.6%
Net Margin
13.2%
ROE
11.1%
Steris keeps about 13.2% of each sales dollar as net profit, with a 44.2% gross margin and 18.6% operating margin. Return on equity is 11.1% and return on invested capital about 10.0%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$1.81B
Net Debt
$1.39B
Net Debt / EBITDA
1.26x
Debt / Equity
0.27x
Leverage: debt-to-equity is 0.3x, and operating profit covers interest about 7.6x, with a current ratio of 2.1x. That is a conservative balance sheet — a cushion in downturns. It carries roughly $1.81B of total debt against $423.70M of cash.
Operating CF
$1.34B
Free Cash Flow
$972.40M
FCF Margin
16.4%
In the latest year Steris produced about $1.34B of operating cash flow and $972.40M of free cash flow after capital spending. That is a free-cash-flow yield of about 5.4% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
25.3x
P/S
3.4x
P/B
2.96x
EV / EBITDA
13.55x
STE trades at 25.3x trailing earnings (about 19.8x on estimated forward earnings), 3.4x sales, and 3.0x book value. Reverse-engineering today's price implies the market expects roughly 3.9% long-term free-cash-flow growth. That is a premium multiple that needs growth to justify it.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How STE stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), STE ranks #21 of 59 by our overall rating. It trades at roughly in line versus the sector on earnings (25.3x P/E vs. 25.4x median) with a lower return on equity (11.1% vs. 14.9%) and faster revenue growth (8.7% vs. 7.9%).
P/E vs sector
25.3x
median 25.4x
ROE vs sector
11.1%
median 14.9%
Growth vs sector
8.7%
median 7.9%
Sector rank
#21
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$182.47 – $304.12
vs. $200.40 today · expected CAGR -2% – 9%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $6.47B | $7.05B | $7.69B | $8.38B | $9.13B |
| Net income | $841.12M | $916.82M | $999.33M | $1.09B | $1.19B |
| EPS | $8.62 | $9.39 | $10.24 | $11.16 | $12.16 |
| Share price (low) | $129.27 | $140.90 | $153.58 | $167.40 | $182.47 |
| Share price (high) | $215.44 | $234.83 | $255.97 | $279.01 | $304.12 |
| CAGR (low–high) | -35% / 8% | -16% / 8% | -8% / 9% | -4% / 9% | -2% / 9% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for STE:
- Healthy free-cash-flow yield (~5.4%) funds buybacks and dividends.
- A conservative balance sheet (debt/equity 0.3x) lowers risk.
- Our model's overall read is Favorable (59/100).
The case against STE:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen favourably: Steris is a large-cap health care business growing at a mature pace, with solid profitability, and a sound balance sheet. It trades at 25.3x earnings, which our model scores Favorable (59/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.